Hospital El Bierzo

Hospital El Bierzo is conducting research focused on Chronic Obstructive Pulmonary Disease, evaluating whether a new triple therapy regimen can provide better clinical control than the standard LABA‑LAMA combination for high‑risk patients.

• Efficacy of triple therapy versus LABA‑LAMA
• Composite endpoint measuring stability and impact
• Targeting GOLD B+ patient subgroup

The trial aims to improve daily functioning and reduce exacerbations for individuals with severe respiratory disease.

In the psychiatry department, investigators are studying Major Depressive Disorder with moderate‑to‑severe anhedonia, testing Aticaprant as an adjunct to existing antidepressants to delay relapse and assess long‑term safety.

• Adjunctive Aticaprant for relapse prevention
• Safety profile over up to one year of treatment
• Focus on patients who have achieved stable response

This work seeks to provide a new option for patients whose depressive symptoms return despite standard therapy.

A study at Hospital El Bierzo examines severe Acute Alcoholic Hepatitis, combining methylprednisolone with N‑acetylcysteine to determine if this approach reduces one‑month mortality.

• Use of corticosteroid plus antioxidant therapy
• Impact on short‑term survival rates
• Targeting patients with high Maddrey scores

The goal is to identify a more effective treatment for a condition that currently has limited therapeutic options.

Researchers are evaluating the optimal length of antimicrobial therapy for Infections associated with osteosynthesis material after long‑bone fractures, comparing surgical debridement with implant retention versus removal.

• Short versus extended antimicrobial courses
• Surgical debridement strategies
• Outcomes of implant retention versus removal

The investigation aims to balance effective infection control with preserving orthopedic stability.